Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aquestive Therapeutics Inc
(NQ:
AQST
)
3.110
-0.170 (-5.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aquestive Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
April 26, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
April 20, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
April 18, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Earnings Outlook For Aquestive Therapeutics
March 06, 2023
Via
Benzinga
Aquestive Inks Supply Pact For Its Seizure Treatment Covering European, Middle East Countries
September 28, 2022
Via
Benzinga
Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction
September 27, 2022
Via
Benzinga
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
March 29, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
March 07, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 01, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
February 22, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 21, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 15, 2023
Via
Benzinga
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
January 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
December 22, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
November 29, 2022
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 15, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
November 09, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Looking Into Aquestive Therapeutics's Return On Capital Employed
November 09, 2022
According to data from Benzinga Pro, during Q3, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $11.46 million. Despite a 23.1% increase in earnings, the company posted a loss of $12.54...
Via
Benzinga
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 01, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Earnings Preview
October 31, 2022
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
October 27, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
October 24, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
October 19, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
October 11, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:AQST Investor Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
September 29, 2022
San Diego, CA -- (SBWIRE) -- 09/29/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation on over potential breaches of fiduciary duties.
Via
SBWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 28, 2022
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million.
Via
Benzinga
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
September 28, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
September 28, 2022
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 27, 2022
Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.
Via
Benzinga
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
September 27, 2022
Aquestive Therapeutics (AQST) stock is taking off Tuesday as investors react to positive clinical trial data from the pharmaceutical company.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.